Daniel E. Hilleman, PharmD
Daniel E. Hilleman, PharmD

Daniel E. Hilleman, PharmD

Director, Continuing Education
School of Pharmacy and Health Professions, Omaha Campus


  • Pharmacy

Academic Appointments


  • Pharmacy Practice


  • Professor

Secondary Appointment

  • Cardiology

Teaching Activity

  • Pharmacy and Medicine


Dr. Hilleman received his PharmD degree from Creighton University (Omaha, NE).  He completed a pre-doctoral research fellowship at the Poison Control Center at Children’s Hospital in Omaha.  Dr. Hilleman joined the faculty at the Creighton University School of Pharmacy in 1981. In 1985, Dr. Hilleman was appointed Director of Clinical Research at the Creighton University Cardiac Center. He held that position until 1993 when he was appointed Chair, Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions. Dr. Hilleman stepped down as Chair in 2004. Dr. Hilleman then completed a one year sabbatical in information technology and distance education at the Center for Technology and Academic Advancement. After completing his sabbatical, Dr. Hilleman has been practicing in Cardiology and Critical Care at Creighton University’s teaching hospital. In 2012, Dr. Hilleman was appointed Director of Continuing Education for the Creighton University School of Pharmacy and Health Professions.
Dr. Hilleman is a Fellow of the American College of Clinical Pharmacy and a Fellow in the American College of Clinical Pharmacology. Dr. Hilleman chairs the University’s Research Conflict of Interest Committee.  He has served on the board of directors of the Nebraska Pharmacists Association and is a member of the National Lipid Association, the American Society of Hypertension, the American Pharmacists Association, the American College of Cardiology and the American Association of Colleges of Pharmacy.  He has authored over 200 peer reviewed publications and five book chapters.

Publications and Presentations


  • Hilleman DE, Campbell J. Medication adherence in heart failure: In: The Kidney in Heart Failure; 2nd Edition. Edited by George Bakris, New York, New York: Springer Science, 2012., Springer Science+Business Media LLC, 2012


  • Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016; 58: 514-528., treatment of depression in patients with concomitant cardiac disease, 2016
  • Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipid in Health and Disease 2016; 15: 118-128., Clinical Lipidology, 2016
  • Hilleman DE, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Managed Care 2016; 25: 46-52., American Journal of Managed Care, 2016
  • Malesker MA, Bruckner AL, Loggie B, Hilleman DE. IV acetaminophen: assessment of medication utilization evaluation data in peri-operative pain management. J Surgery 2015; 10:6-10., Journal of Surgery, 10, 6-10, 2015
  • Hilleman DE, Burns TL. Update on recently approved pharmacotherapy in the management of obesity. Nebraska Mortar & Pestle 2015; Mar/Apr: 19-27., Nebraska Mortar and Pestle, 19-27, 2015
  • Au, T. H., Bruckner, A., Mohiuddin, S. M., Hilleman, D. E. The prevention of contrast-induced nephropathy, Annals of Pharmacotherapy, 48, 1332-1342, 2014
  • Ling, Hua, Burns, Tammy L., Hilleman, Daniel E. An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol, Cardiovascular Therapeutics, 32, 82-88, 2014
  • Campbell, JA, Teply, R., Mooss, AN, Hilleman, DE Impact of grapefruit juice on the antiplatelet activity of loading and maintenance doses of clopidogrel in healthy volunteers., Cardiology Research, 5, 32-38, 2014
  • Hilleman, DE, Malesker, MA Potenial benefits of icosapent ethyl on the lipid profile: case studies., Clinical Medicine Insights: Cardiology, 8, 13-15, 2014
  • Hilleman, D. E. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management, Journal of Managed Care Pharmacy : JMCP, 20, 93-100, 2014
  • Au TH, Bruckner A, Mohiuddin SM, Hilleman DE. The prevention of contrast-induced nephropathy. Annals of Pharmacotherapy 2014; 48: 971-976., Pharmacotherapy, 48, 971-976, 2014
  • Gorthi J, Hunter CB, Mooss AN, All VM, Hilleman DE. Reducing heart failure readmissions: a systematic review of disease management programs. Cardiol Res 2014; 5: 126-138., Cardiology Research, 5, 126-138, 2014
  • Packard K, Gibu M, Teply R, Hilleman D, Qi Y. Pharmacy student intervention acceptance on a cardiology rotation. Pharmacy Education 2014; 14: 64-69., Pharmacy Education, 14, 64-69, 2014
  • Ling, Hua, Lenz, Thomas L., Burns, Tammy L., Hilleman, Daniel E. Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs, Pharmacotherapy, 33, 1308-1321, 2013
  • Ling, Hua, Packard, Kathleen A., Burns, Tammy L., Hilleman, Daniel E. Impact of Ranolazine on Clinical Outcomes and Healthcare Resource Utilization in Patients with Refractory Angina Pectoris, American Journal of Cardiovascular Drugs, 13, 407-412, 2013
  • Hilleman, Daniel E. Optimal use of lipid-altering therapy: guidelines versus evidence, Clinical Lipidology, 8, 269-272, 2013
  • Burns, Tammy L., Ruckman, Jilyan A., Ling, Hua, Washington-Krauth, Shavonne M., Hilleman, Daniel E., Mohiuddin, Syed M. Current State of United States Tobacco Control Initiatives, World Medical & Health Policy, 5, 245-259, 2013
  • Ling H, Luoma JT, Hilleman DE. A review of currently available fenofibrate and fenofibric acid formulations. Cardiol Res 2013: 4: 47-55., Cardiology Research, 4, 47-55, 2013
  • Bradberry JC, Hilleman DE. Omega-3 fatty acids: overview of current therapies. P & T 2013: 38: 681-691., Pharmacy and Therapeutics, 38, 681-691, 2013
  • Malesker, Mark A., Hilleman, Daniel E. Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically Ill patients, Journal of Critical Care, 27, 528.e7-528.e14, 2012
  • Hawkins EB, Ling H, Burns TL, Mooss AN, Hilleman DE. Aliskiren in patients failing to achieve blood pressure targets with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Cardiology Res 2012; 3:147-153., Cardiology Research, 3, 147-153, 2012
  • Hilleman DE. New oral anticoagulants for stroke prevention in atrial fibrillation. Am J Pharmacy Benefits 2012; 4: 356-362., American Journal of Pharmacy Benefits, 4, 356-362, 2012
  • Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgraduate Medicine 2012; 124: 43-54., Postgraduate Medicine, 124, 43-54, 2012
  • Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emergency Med 2012; 30: 981-983., American Journal of Emergency Medicine, 30, 981-983, 2012
  • Deshmukh A, Hilleman D, Del Core M, Nair CK. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions – systematic analysis, review of literature, and implications on management. Am J Ther 2011; 18: 203-210., American Journal of Therapeutics, 18, 203-210, 2011
  • Dewan NA, Rice KL, Caldwell M, Hilleman DE. Economic evaluation of a disease management program for chronic obstructive pulmonary disease. J Chronic Pulm Dis 2011; 8: 153-159., International journal of chronic obstructive pulmonary disease, 8, 153-159, 2011
  • Go J, Narmi A, Sype J, Mooss AN, Hilleman DE. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. Coronary Artery Disease 2011; 22: 411-415., Coronary Artery Diesease, 22, 411-415, 2011
  • Hilleman DE, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy 2011; 31: 1031-1040., Pharmacotherapy, 31, 1031-1040, 2011
  • Campbell, J., Hilleman, D. Recombinant Peptides in Thrombolysis, Seminars in thrombosis and hemostasis, 36, 529-536, 2010
  • Packard, K. A., Hilleman, D. E., Davis, Estella M. Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers, Pharmacotherapy, 30, 749, 2010
  • Malesker, M. A., Hilleman, D. E. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy, Managed Care, 19, 36-42, 2010
  • Campbell, Jennifer, Hilleman, Daniel Reducing cardiovascular risk in patients with type 2 diabetes: management of dyslipidemia, Formulary, 45, 124-134, 2010
  • Schima, S. M., Maciejewski, S. R., Hilleman, D. E., Williams, M. A., Mohiuddin, S. M. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid, Expert Opinion on Pharmacotherapy, 11, 731-738, 2010
  • Teply, Robyn M., Campbell, J., Hilleman, D. Current trends in the treatment of asthma: focus on simultaneous administration of salmeterol/fluticasone, Journal of Asthma and Allergy, 3, 1-8, 2010
  • Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD, Chest, 136, e30, 2009
  • Hilleman, D. E., Malesker, M. A., Morrow, L. E., Schuller, D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD, International journal of chronic obstructive pulmonary disease, 4, 253-263, 2009
  • Maciejewski, S., Hilleman, D. Effettiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia, Pharmacotherapy, 28, 570-575, 2008
  • Hilleman, D. E., Razavi, M. K. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis, Journal of Vascular and Interventional Radiology, 19, 377-383, 2008
  • Coover, K., Ryan-Haddad, Ann, Faulkner, M., Hilleman, Daniel E. Prevalence, treatment and control of hypertension in residents of skilled nursing facilities, Consultant Pharmacist, 23, 317-323, 2008
  • Hilleman, Daniel E., Tsikouris, James P., Seales, Allen, Marmur, Jonathan D. Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction, Pharmacotherapy, 27, 1558-1570, 2007
  • Malesker, M. A., Foral, P. A., McPhillips, A. C., Christensen, K. J., Chang, J. A., Hilleman, D. E. An efficiency evaluation of protocols for tight glycemic control in intensive care units, American Journal of Critical Care, 16, 589-598, 2007
  • Burns, T., Madejewski, S. R., Hamilton, W. R., Zheng, M., Mooss, A. N., Hilleman, D. E. Effect of omega-3 fatty acid supplementation on the arachidonic acid: Eicosapentaenoic acid ratio, Pharmacotherapy, 27, 633-638, 2007
  • Buckley, M. S., Nolan, P. E., Slack, M. K., Tisdale, J. E., Hilleman, D. E., Copeland, J. G. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: Meta-analysis of dose response and timing of initiation, Pharmacotherapy, 27, 360-368, 2007
  • Simpson, D., Siddiqui, M. A. A., Scott, L. J., Hilleman, D. E. Spotlight on reteplase in thrombotic occlusive disorders, Biodrugs, 21, 65-68, 2007
  • Van den Berghe, G., Wouters, P. J., Kesteloot, K., Hilleman, D. E. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients, Critical Care Medicine, 34, 612-616, 2006
  • Maciejewski, S., Mohiuddin, S. M., Packard, K. A., Mooss, A. N., Reyes, A. P., Aryana, A., Hilleman, D. E. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African- Americans with hypertension using 24-hour ambulatory blood pressure monitoring, Pharmacotherapy, 26, 889-895, 2006
  • Hilleman, D. E. Cost considerations with tight glycemic control in the acute care setting, International Journal of Cardiology, 18, 359-365, 2006
  • Burns, T. L., Mooss, A. N., Hilleman, D. E. Antiplatelet drug resistance: Not ready for prime time, Pharmacotherapy, 25, 1621-1628, 2005
  • Hilleman, D. E., Hunter, C. B., Mohiuddin, S. M., Maciejewski, S. Creighton University Cardiac Center, Omaha, NE, USA; Pharmacological management of atrial fibrillation following cardiac surgery, American Journal of Cardiovascular Drugs, 5, 361-369, 2005
  • Hilleman, D. E. New treatment options in COPD, Journal of Managed Care Pharmacy, 11, S12-S19, 2005
  • Packard, K. A., Majeed, F., Mohiuddin, S. M., Mooss, A. N., Hilleman, D. E., Arouni, A. J. Low high-density lipoprotein cholesterol is associated with impaired endothelial function in Asian Indians, Ethnicity and Disease, 15, 555-561, 2005
  • Lenz, T. L., Foral, P. A., Malesker, M. A., Hunter, C. B., Hilleman, D. E. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure, Pharmacotherapy, 24, 1137-1146, 2004
  • Hilleman, D. E., Faulkner, M. A., Monaghan, M. S. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia, Pharmacotherapy, 24, 1077-1083, 2004
  • Hilleman, D. E., Lucas, B. D. Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction?, Pharmacotherapy, 24, 1064-1076, 2004
  • Sarac, T. P., Hilleman, D., Arko, F. R., Zarins, C. K., Ouriel, K. Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions: Preliminary analysis, Journal of Vascular Surgery, 39, 556-559, 2004
  • Foral, P. A., Malesker, M. A., Huerta, G., Hilleman, D. E. Nebulized opioids use in COPD, Chest, 125, 691-694, 2004
  • Faulkner, M. A., Hilleman, D. E. Pharmacologic treatment of chronic obstructive pulmonary disease: Past, present, and future, Pharmacotherapy, 23, 1300-1315, 2003
  • Hilleman, D. E. Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia, Formulary, 38, 478-497, 2003
  • Hilleman, D. E., Spinler, S. A. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: A meta-analysis of randomized controlled trials, Pharmacotherapy, 22, 66-74, 2002
  • Hilleman, D. E. Pharmacoeconomics of combination antihypertensive therapy, Blood pressure monitoring, 6, S31-S36, 2001
  • Nair, C. K., Khan, I. A., Esterbrooks, D. J., Ryschon, K. L., Hilleman, D. E. Diagnostic and prognostic value of holter-detected ST-segment deviation in unselected patients with chest pain referred for coronary angiography - A long-term follow-up analysis, Chest, 120, 834-839, 2001
  • Faulkner, M. A., Hilleman, D. E., Destache, C. J., Mooss, A. N. Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome, Pharmacotherapy, 21, 1055-1060, 2001
  • Hilleman, D. E., Reyes, A. P., Wurdeman, R. L., Faulkner, M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension, Journal of human hypertension, 15, 559-565, 2001
  • Lenz, T. L., Wurdeman, R. L., Hilleman, D. E. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine, Pharmacotherapy, 21, 898-903, 2001
  • Spinler, S. A., Hilleman, D. E., Cheng, J. W.M., Howard, P. A., Mauro, V. F., Lopez, L. M., Munger, M. A., Gardner, S. F., Nappi, J. M. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines, Annals of Pharmacotherapy, 35, 589-617, 2001
  • Hilleman, D. E., Bauman, J. L. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review, Pharmacotherapy, 21, 556-575, 2001
  • Hilleman, D. E., Wurdeman, R. L., Lenz, T. L. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease, Pharmacotherapy, 21, 410-415, 2001
  • Friedman, M., Hilleman, D. E. Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options, Pharmacoeconomics, 19, 245-254, 2001
  • Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD, Chest, 118, 1278-1285, 2000
  • Lenz, T. L., Hilleman, D. E. Aggrenox: A fixed-dose combination of aspirin and dipyridamole, Annals of Pharmacotherapy, 34, 1283-1290, 2000
  • Lenz, T. L., Hilleman, D. E. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter, Drugs of Today, 36, 759-771, 2000
  • Hilleman, D. E. Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension, American Journal of Health-System Pharmacy, 57, S8-S11, 2000
  • Hilleman, D. E. New approaches to the management of AMI: Fibrinolysis plus GP IIb/IIIa receptor blockade, Formulary, 35, 738-751, 2000
  • Hilleman, D. E., Heineman, S. M., Foral, P. A. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study, Pharmacotherapy, 20, 819-822, 2000
  • Mooss, A. N., Wurdeman, R. L., Mohiuddin, S. M., Reyes, A. P., Sugimoto, J. T., Scott, W., Hilleman, D. E., Seyedroudbari, A. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery, American Heart Journal, 140, 176-180, 2000
  • Skrabal, M. Z., Stading, J. A., Behmer-Miller, K. A., Hilleman, D. E. Advances in the treatment of congestive heart failure: New approaches for an old disease, Pharmacotherapy, 20, 787-804, 2000
  • Lenz, T. L., Hilleman, D. E. Dofetilide, a new class III antiarrhythmic agent, Pharmacotherapy, 20, 776-786, 2000
  • Seyedroudbari, A., Kessler, E. R., Mooss, A. N., Wurdeman, R. L., Bala, M., Hilleman, D. E. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA, Journal of Thrombosis and Thrombolysis, 9, 303-308, 2000
  • Faulkner, M. A., Wadibia, E. C., Lucas, B. D., Hilleman, D. E. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial, Pharmacotherapy, 20, 410-416, 2000
  • Hilleman DE, Mohiuddin SM. Collaborative obesity management: advanced practice clinicians working with patients. Convenient Care 2015; 9: 20-21., convenient care
  • Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? Lipid Spin 2016; 14: 29-31., Clinical Lipidology


  • Hilleman DE, Malesker MA. Utilization of dabigatran in patients with atrial fibrillation: impact of the ACCP guidelines and the SAMe-TT2R2 score. J Man Care Pharm 2015; 21: S47., Journal of Managed Care & Specialty Pharmacy, 21, S47, 2015
  • Deshmukh A, Patel N, Azzouz M, Haroon S, Hilleman DK, Kaushik M, White M, DelCore M, Mooss A, Esterbrooks D, Lanspa T. Efficacy and safety of transradial approach to renal artery interventions. J Am Coll Cardiol Intv 2014; 7(2S): S38., 7(2S), S38, 2014
  • Deshmukh A, Patel N, Kandasamy V, Hilleman DE, et al. Radial versus femoral approach to high speed rotational atherectomy. J Am Coll Cardiol Intv 2014; 7: S29-S30., 7, s29-s30, 2014
  • Au T, Malesker M, Hilleman DE, et al. A retrospective analysis of dexmedetomidine use for alcohol withdrawal syndrome in critical care patients. Chest 2014; 146: 225A., Chest, 146, 225A, 2014
  • Malesker MA, Hawkins E, Hilleman DE, Morrow LE. Intermittent bolus dosing vs continuous infusion furosemide in ICU patients with diuretic resistance. Crit Care Med 2013; 41:3 (abstract)., Critical Care Medicine, 41, 3, 2013
  • Hilleman D, Ling H, Luoma J. A review and comparison of fenofibrate and fenofibric acid formulations available in the United States. American Academy of Nurse Practitioners; June 2012; Orlando, FL. Abstract 24., 2012
  • Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A., Chest, 142, 402A, 2012
  • Hawkins E, Ling H, Burns T, Hilleman D. Perceptions, knowledge, and patterns of use of “fish oil” products in cardiac patients. Pharmacotherapy, 2012; 32: e184., Pharmacotherapy, 32, e184, 2012
  • Hawkins E, Ling H, Burns T, Mooss A, Hilleman D. Aliskiren in patients failing to achieve blood pressure targets with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Pharmacotherapy 2012; 32: e184., Pharmacotherapy, 32, e184, 2012
  • Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A., Chest, 142, 402A, 2012
  • Kaushik M, Deshmukh A, Pandva J, Hilleman D, Esterbrooks D, Mohiuddin S. Echocardiographic correlates of persistent ST-elevation on ECG in STEMI patients undergoing percutaneous coronary intervention. JACC 2012; 60 (suppl B): B148., 60, B148, 2012
  • Malesker, MA, Boldt D, Ling H, Burns T, Hilleman DE. Impact of the ACCP antithrombotic guidelines on potential utilization of dabigatran in patients with atrial fibrillation. Chest 2013; 144: 161A., Chest, 144, 161A, 2012


  • Packard KA, Hilleman DE. Adherence to therapies for secondary prevention of cardiovascular disease: focus on aspirin. Cardiovascular Ther 2016; 34: 415-422., Cardiovascular Therapeutics, 2016

Research and Scholarship

Research and Scholarship Interests

  • Cardiology
    Critical Care

Current Research Projects

  • Cardiology
    Critical Care